Registry for cardiac amyloidosis patients in Switzerland
Official title: Swiss Cardiac Amyloidosis REgistry (Swiss-CARE)
Run by Insel Gruppe AG, University Hospital Bern · NCT04776824 · Data updated 2026-11-12
This study is collecting information from patients with cardiac amyloidosis in Switzerland to see how their condition changes over time and to find out who might benefit from a new treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 7 sites (Basel and 6 other locations) |
| Status | Recruiting |
| Started | February 22, 2001 |
| Main results expected | May 1, 2031 |
| Study ends | May 1, 2031 |
| Registry record updated | November 4, 2026 |
| Trial ID | NCT04776824 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with a confirmed diagnosis of amyloidosis, with or without cardiac involvement.
✕Probably not a fit
Patients under 18 years of age or those unable to provide consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and analyze data from patients diagnosed with cardiac transthyretin amyloidosis (ATTR) at the Inselspital Bern. It will utilize cardiac magnetic resonance imaging (CMR) techniques, including feature tracking and T1- and T2-mapping, to identify markers that indicate disease severity and help determine which patients may benefit from TTR stabilization treatment. The study will follow patients over 18 months, with clinical and laboratory assessments conducted every 3-6 months to monitor therapy response and disease progression.
Why it matters
Potential benefit: If successful, this study could improve patient selection for TTR stabilization therapy, leading to better treatment outcomes.
How similar studies have gone: While there have been studies on cardiac amyloidosis, this approach focusing on CMR feature tracking and mapping for patient selection is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of amyloidosis w/wo cardiac involvement * General Consent Exclusion Criteria: * Inability to give consent or existence of a written or documented oral refusal of the data subject.\<18 years of age
Where it's running
-
Usb
Basel, Switzerland Recruiting -
Department of Cardiology, University Hospital Bern, Inselspital, Bern
Bern, Switzerland Recruiting -
Hug
Geneva, Switzerland Recruiting -
Chuv
Lausanne, Switzerland Recruiting -
Luks
Lucerne, Switzerland Recruiting -
Kssg
Sankt Gallen, Switzerland Recruiting
Show 1 more location
-
Stadtspital Triemli
Zurich, Switzerland Recruiting
Study contacts
- Principal investigator: Christoph Gräni, MD, PhD — Department of Cardiology, University Hospital Bern, Inselspital, Bern
- Study coordinator: Christoph Gräni, MD, PhD
- Email: christoph.graeni@insel.ch
- Phone: +41 31 632 4508
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Acoramidis for ATTR-CM: Cardiac Imaging Study
This study tests whether acoramidis can improve heart structure and function in people with transthyretin amyloid cardiomyopathy.
-
Hungarian National Systemic Amyloidosis Registry
This registry collects medical data from adults with systemic amyloidosis across Hungary to help understand how the disease is diagnosed and treated in real-world practice.
-
Cardiac MRI blood-flow imaging to distinguish types of hypertrophic cardiomyopathy
We will try cardiac MRI perfusion imaging to see if blood-flow patterns can distinguish people with different forms of hypertrophic cardiomyopathy, including genetic carriers and related conditions like Fabry disease and cardiac amyloidosis.
-
Enavogliflozin for Amyloid Cardiomyopathy
This study tests whether Enavogliflozin helps people with amyloid cardiomyopathy and heart failure by comparing it to placebo in two treatment periods.
-
Investigating genistein for treating amyloid cardiomyopathy
This study is testing if genistein can safely help people with amyloid cardiomyopathy improve their heart health and exercise ability.
-
Preventing transthyretin amyloidosis in young carriers of a genetic variant
This study is testing if a medication called acoramidis can help prevent transthyretin amyloidosis in young adults who carry a specific genetic variant that puts them at risk for the disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.